JAM 25 ZOUS CONTROLLED

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

ed to respond to a collection of information unless it contains a valid OMB control number.				
Complete if Known				
Application Number	10/692002			
Filing Date	October 24, 2003			
First Named Inventor	Mike West			
Art Unit	1644			
Examiner Name Not Yet Assigned				
Attorney Docket Number	DU-P02-002			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

		FOREIG	N PATENT	DOCUMENTS		_
Examiner	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
171102315						L

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.usolo.gov">www.usolo.gov</a> or MPEP 901.04. \*Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
xaminer	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city	T
1111013	CA	SELLKE,T. et al., Calibration of pvalues for testing precise null hypotheses, The American	_
	CA		
	СВ	Statistician, 55, 62-71, (2001)  BREIMAN, L., Statistical Modeling: The two cultures (with discussion). Statistical Science, 16	÷
	CB	1466 60E (2001)	<u> </u>
	CC	CORPORATE R.G. Applications of near infrared reflectance spectroscopy to compositional	_
	-	The state and bigguit doughs I Sci FOOD ADDC, 35, 99-100 (1904)	_
	00	TROWN R.L. et al. The choice of variables in multivariate regression. A not reciplosate	L
	CD	)	L
	0=	ILL C. et al. Model-based analysis of oligonucleotide arrays. Expression index competence	Ļ
	CE		L
	CF	TEAST COSE ACT CANCED TOTALISTS COLLABORATIVE GROUP, Polychomochorpy (*)	L
_	ICF	I reduce to ancer: an overview of the randomized thats, , Lancet, 532.530-542 (2001)	F
	CG	WEST M et al. Predicting the clinical status of human preast caricer by using gene	Ļ
	100	1 Bros Natl Acad Sci USA 98, 11462-11467 (2001)	╄
	СН	SPANG, R., et al., Prediction and uncertainty in the analysis of gene expression profiles, In	L
	Un.		╀
	Ci	VAN T VEER, L.J., et al., Gene expression profiling predicts clinical outcome of breast cancer.	+
	101	TO 1 - 14 E 620 E26 (2002)	1
	CJ	VAN DE VIJVER, M.J., et al., A gene-expression signature as a predictor of survival in breast	+
_	10		+
	Ċĸ	HUANG, E., et al., Gene expression predictors of breast cancer outcomes., Lancet in press	4
	CK		+
	CL	POMEROY, S.L., et al., Prediction of central nervous system embryonal tumour outcome	1
_	CL		4
	СМ	ALIZADEH, A.A., et al., Distinct types of diffuse large B-cell lymphoma identified by gene	+
_	CIVI	Neturo 703 503-511 (2000)	+
	CN	ROSENWALD, A., et al., The use of molecular profiling to predict survival after chemotherapy	4
_	TON-	for diffuse large-B-cell lymphoma.	ᆚ

	Date	05/17/2006
Examiner /Jerry Lin/	Considered	03/11/2000
Signature / UEITY IIII/		

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Union the raphila resources				Complete if Known		
Sul	Substitute for form 1449A/B/PTO			Application Number	10/692002	
11	NFORMATION	I DI	SCLOSURE	Filing Date	October 24, 2003	
	STATEMENT BY APPLICANT (Use as many she ets as necessary)			First Named Inventor	Mike West	
. 3				Art-Unit · ·	1644	
				Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	DU-P02-002	

CO	BHATTACHARJEE, A., et al., Classification of human lung carcinomas by mRNA expression
	profiling reveals distinct adenocarcinoma subclasses, Proc. Natl. Acad. Sci. USA 98, 13790-
1	13795 (2001)
CP	RAMASWARNY, S., et al., Multiclass cancer diagnosis using tumor gene expression
<u> </u>	signatures, Proc. Nat'l, Acad. Sci. 98, 15149-15154 (2001)
CQ	GOLUB, T.R., et al., Molecular classification of cancer: class discovery and class prediction by
00	The state of the s
CR	SHIPP, M.A., et al., Diffuse large B-cell lymphoma outcome prediction by gene expression
	profiling and supervised machine learning, Nat. Med. 8, 68-74 (2002)
cs ·	VEOU E - L et al. Classification subtype discovery, and prediction of outcome in pediatric
Co	acute tymphobiastic teukemia by gene expression profiling, Cancer Cell 1,133-143 (2002)
CT.	CHENC, et al., Unique Features of Breast Cancer Res. Treat. 2000.03.213-23)
<u> </u>	MITTRA, I., et al., A Meta-analysis of reported correlations between prognostic factors in
CU	breast cancer: does axillary lymph node metastasis represent biology or chronology,
•	Eur. J. Cancer 1991;27:1574-83
<u>~</u>	McGUIRE, W.L., Prognostic factors for recurrence and survival in human breast cancer,
CV	Breast Cancer Res Treat. 1987; 10:5-9
0)4/	TANDON, A.K., et al., HER-2/neu oncogene protein and prognosis in breast cancer, JClin.
CW	
CY	Ontol: 1989,7:1120-8 IVASS, R.E., et al., Bayes' feeters, J. Am. Stat. Asses, 90, 773 795 (1999)
	HOETING, J., et al., Bayesian model averaging, A tutorial; Statistical Science, 14(4), 382-417
CY	
	(1999) CLYDE M. Bayesian Statistics 6. Bernardo J.M. (ed.), pp. 157-185 (Oxford University Press,
CZ	
	JATOI, I., Significance of axillary lymph node metastasis in primary breast cancer. J. Clin.
CA1	JATOI, I., Significance of axiliary lymph flode filetastasis in silmary 5.555, Constitution
	Oncol. 17, 2334-2340 (1999) PHILOSOPHOV, L. et al., Medical Diagnostic Decision Rules Based on Mutually Dependent
CB1	PHILOSOPHOV, L. et al., Medical Diagnostic Decision rolles based on ministering September 1997
	Diagnostic Factors, Comput. Biol. Med., Vol. 27, No. 4, 329-347, 1997.  LIAO, S. et al., Appropriate medical data categorization for data mining classification.
CC1	LIAO, S. et al., Appropriate medical data categorization for data mining control of the categories of
	Techniques, Med. Inform. Vol. 27, No. 1, 59-67 (2002).  CHAPMAN, W. et al., A Comparison of Classification Algorithms to Automatically Identify
CD1	CHAPMAN, W. et al., A Comparison of Classification Agont into the Action Action at Comparison of Classification Agont into the Action at Comparison of Classification at Classif
<u> </u>	(2001).
CF1	DAWSON, K., et al., A Bayesian approach to the identification of panmictic populations and
	the assignment of individuals", Genet. Res. Camb., 78, 59-77 (2001).
CF1	Copy of International Search Report dated July 1, 2004 from corresponding application no.
	PCT/USU3/33946; citing references PHILOSOPHOV, LIAO, CHAPMAN and DAWSON.
CG1	TOOD IE T of all Gane expression natterns of breast carcinomas distinguish turnor
	subclasses with clinical implications, PNAS, Vol. 98, No. 19, 10869-10874 (2001)
<b>CH1</b>	DYIAEOELEER at cl. Bioinformatics, Volume 10, pages 707-720 (2000)

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			<del></del>
Examiner Signature	/Jerry Lin/	Date Considered	05/17/2006
Signature			· · · · · · · · · · · · · · · · · · ·

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English tanguage Translation is attached.